p62/SQSTM1 levels predicts radiotherapy resistance in hypopharyngeal carcinomas.
p62/SQSTM1 levels predicts radiotherapy resistance in hypopharyngeal carcinomas.
复制标题
DOI：
--
复制
发表时间：
2017-04
影响因子：
5.3
通讯作者：
A. Arai;T. Chano;K. Ikebuchi;Y. Hama;Yasuko Ochi;Hitosuke Tameno;Taketoshi Shimada
中科院分区：
文献类型：
--
作者：
A. Arai;T. Chano;K. Ikebuchi;Y. Hama;Yasuko Ochi;Hitosuke Tameno;Taketoshi Shimada
下咽癌是头颈部恶性肿瘤中预后最差的肿瘤之一。因此，在开始治疗之前，应该确定一个好的生物标志物来预测最佳的治疗选择。在细胞模型中，p62/SQSTM 1水平影响Nrf 2-Keap 1通路、ROS水平、GSH/GSSG比率和细胞生长，特别是在辐射下而不是在CDDP暴露下，尽管p62/SQSTM 1状态是有毒的。在下咽癌的临床队列中，高水平的p62/SQSTM 1显著预测不良预后（对数秩检验，卡方值= 6.750，P = 0.0094）和最大临界风险（考克斯比例风险比= 4.405，P = 0.0086），尤其是在放疗组。因此，当活检切片中p62/SQSTM 1升高时，下咽癌应采用手术和/或化疗方案治疗。
Hypopharyngeal carcinoma is one of the worst prognostic malignancies among head and neck carcinomas. Therefore, a good biomarker should be identified to predict the best therapeutic option before starting the treatment. In cell models, p62/SQSTM1 levels affected the Nrf2-Keap1 pathway, ROS levels, GSH/GSSG ratios and cell growth, especially under irradiation rather than under CDDP exposure, which was toxic despite p62/SQSTM1 status. In a clinical cohort of hypopharyngeal carcinomas, high levels of p62/SQSTM1 significantly predicted poor prognosis (log-rank test, Chi-square value = 6.750, P = 0.0094) and maximum critical risk (Cox proportional hazard ratio = 4.405, P = 0.0086), especially in the radiotherapy group. Therefore, when p62/SQSTM1 is elevated in the biopsy section, hypopharyngeal carcinoma should be treated with surgical and/or chemotherapeutic options.